Role of antiestrogens and aromatase inhibitors in breast cancer treatment
- 1 February 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 14 (1) , 5-12
- https://doi.org/10.1097/00001703-200202000-00002
Abstract
This review explores the recent experience with, and the basis for, the use of selective estrogen receptor modulators to treat and prevent breast cancer. As new agents are unveiled, they will continue to be tested against tamoxifen. A number of new selective estrogen receptor modulators are in clinical development in an attempt to decrease the unwanted effects of tamoxifen. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. Additionally, two different classes of hormonal agents, the aromatase inhibitors and estrogen receptor down-regulators, which have no estrogen-like properties at any site, appear to be promising new treatments for advanced breast cancer.Keywords
This publication has 43 references indexed in Scilit:
- National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000JNCI Journal of the National Cancer Institute, 2001
- Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized TrialJNCI Journal of the National Cancer Institute, 2001
- Tamoxifen and Chemotherapy for Axillary Node-Negative, Estrogen Receptor–Negative Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-23Journal of Clinical Oncology, 2001
- Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control studyThe Lancet, 2000
- Selective oestrogen receptor modulation: molecular pharmacology for the millenniumEuropean Journal Of Cancer, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI Journal of the National Cancer Institute, 1996
- Systemic Therapy in Patients with Node-Negative Breast CancerAnnals of Internal Medicine, 1989